Lipid Nanoparticle Production for mRNA Delivery: Comparison of Different Turbulent Mixing Technologies

Vogler J.

leon-nanodrugs GmbH, Munich, Germany

WEBSITE: www.leon-nanodrugs.com EMAIL: j.vogler@leon-nanodrugs.com




PURPOSE

mRNA-loaded lipid nanoparticles (LNPs) have revolutionized vaccines & gene therapy drug products. Turbulent mixing has proven to be the preferred manufacturing technology for high-volume production due to its ease of scale-up compared to e.g. microfluidics.

Here, we show comparative data on jet impinging technology from LEON vs. conventional T-junction mixing to evaluate the impact of the mixing technology on the particle properties and *in vivo* transection efficiency. A clinically relevant lipid composition loaded with polyA surrogate or firefly luciferase (FLuc) mRNA as reporter system was used.

METHODS

Mixing technologies:







Figure 1. LEON impinging jet mixer


Figure 2. Conventional T-junction mixer


- LNP production: LNPs were produced by mixing a lipid solution consisting of ionizable cationic lipid/Cholesterol/DSPC/PEG-Lipid in ethanol with a buffered aqueous solution containing polyA or FLuc mRNA. A flow rate ratio (FRR) of 2:1, 3:1 and 4:1 as well as a total flow rate (TFR) of 40 ml/min and 80 ml/min was selected for the manufacturing of polyA loaded LNPs using the LEON impinging jet mixer. Results were compared with LNPs produced with a FRR of 3:1 and TFR of 40 ml/min using a conventional T-junction mixer. Subsequently Fluc mRNA LNPs were manufactured at a FRR of 3:1 and TFR of 40 ml/min with both LEON impinging jet mixer and conventional T-junction mixer. All samples were dialyzed against PBS pH 7.4 without prior dilution.
- Particle characterization: Particle size & poly dispersity index (PDI) were determined by dynamic light scattering (DLS) using a Malvern Zetasizer (Zetasizer Nano ZS, Malvern, UK).
- Encapsulation efficiency: Encapsulated mRNA was quantified using a fluorogenic RiboGreenTM RNA assay kit.
- *In vivo* transfection assay: 5 mice each received a single IV (tail vain) injection of 0.3 mg/kg or 1 mg/kg mRNA-loaded LNPs produced with the LEON impinging jet reactor or a conventional T-junction mixer. Bioluminescence of liver homogenates was determined 4 h after LNP administration.


RESULTS

Both mixing technologies generated polyA and FLuc-mRNA loaded LNPs with comparable size, PDI, encapsulation efficiency (EE%) (Table 1), morphology (Figure 3) and in vivo activity (Figure 2).












Figure 3. Cryo-TEM images of FLuc mRNA loaded LNPs produced with LEON impinging jet reactor or conventional T-piece. White arrows indicate spherical LNPs. Pink arrows indicate spheroid frost which are sample preparation artifacts and not indicative of LNP characteristics.

- The variation of FRR for polyA loaded LNPs produced with LEON impinging jet reactor showed little impact on the particle properties with FRR=3:1 resulting in the smallest size and PDI. Increasing the TFR from 40 ml/min to 80 ml/min did not result in a substantial change in size and PDI when using the LEON impinging jet reactor.
- Both mixing technologies result in homogenous spherical particles according to cryo-TEM analysis.

CONCLUSIONS

- ✓ LEON's impinging jet reactor technology enables the manufacturing of mRNA loaded LNPs with small size, low PDI and high encapsulation efficiency.
- ✓ LNPs produced with LEON's impinging jet reactor technology are comparable with LNPs produced with a conventional T-piece mixer in terms of particle size, PDI, EE%, morphology, and in vivo activity.
- ✓ LNP characteristics (size, PDI, EE%) of particles produced with LEON's impinging jet reactor technology are consistent over a wide range of total flow rates (40 − 80 ml/min tested).
- ✓ The collected scientific data demonstrate once again the quality of LEON's process technology to support product design and development based on LEON's expertise and its data driven approach.

ACKNOWLEDGMENT

We thank Acuitas Therapeutics (Vancouver) for the collaborative support on the present work.

